Patients with brain tumors are in desperate need of new therapies, such as those that inhibit new vessel formation (angiogenesis). Recent clinical testing of angiogenesis inhibitors has accentuated the need for non-invasive measures of tumor vasculature. Therefore, the long-term goal of this first-time competitive renewal application is to develop MRI contrast agent methods that efficiently evaluate the clinical potential of anti-angiogenic therapies. The general hypothesis is that MR contrast-agent methods will provide relevant markers of tumor angiogenesis if the biophysical relationships underlying these methods are well characterized. Excellent progress has been made in this regard, especially considering that the initial 5 year proposal was awarded 3 years of funding. Simulations and experiments, made in a rat brain tumor model, using contrast-agent T1 methods demonstrate that an accurate measurement of tissue blood volume fraction depends profoundly on the choice of imaging sequence and parameters. Studies to characterize the susceptibility-based blood volume measurements have shown that the susceptibility calibration factor is different for tumor and normal brain tissue, a new finding that may be due to the differences in vascular geometry. Treatment of the rat 9L gliosarcoma with the steroid dexamethasone demonstrated a vessel-size selective effect, which may parallel the balance of angiogenic factors. Using a novel GE(gradient-echo)/SE(spin-echo) imaging method we demonstrated that dynamic susceptibility contrast (DSC) measures of total and microvascular rCBV (relative cerebral blood volume), along with vessel size information could be obtained from patients with brain tumors. Total rCBV and vessel diameter information ware found to be statistically different between low and high-grade tumors. Discerning this difference depends on the proper consideration of contrast agent extravasation effects.
The specific aims are logical and exciting extensions of the initial aims. We will continue to develop and validate the susceptibility contrast methods for measuring blood volume and vessel diameter with i. the development of a novel tumor-specific simulation model and ii. MRI and histology measurements made in a rat 9L gliosarcoma model (Aim 1). The usefulness of these methods to track changes with therapy will be evaluated (Aim 2). Tumor-appropriate methods to measure cerebral blood flow (CBF) will be developed and validated (Aim 3). The optimized CBV, CBF methods will be applied to brain tumor patients and correlated with relevant immunohistochemical markers (Aim 4). Significance: Completion of these studies should move us closer to the ultimate goal of dramatically improving the diagnosis and management of patients with vascular tumors such as gliomas. Novelty: A key unique component of the proposed studies is the characterization of the biophysical relationships underlying the proposed methods. This will not only aid in assessing the accuracy of the techniques, but will also help us to exploit the wealth of information that can be derived from such measurements.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA082500-06
Application #
6870157
Study Section
Diagnostic Radiology Study Section (RNM)
Program Officer
Liu, Guoying
Project Start
2000-03-01
Project End
2007-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
6
Fiscal Year
2005
Total Cost
$282,000
Indirect Cost
Name
Medical College of Wisconsin
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Chitambar, Christopher R; Al-Gizawiy, Mona M; Alhajala, Hisham S et al. (2018) Gallium Maltolate Disrupts Tumor Iron Metabolism and Retards the Growth of Glioblastoma by Inhibiting Mitochondrial Function and Ribonucleotide Reductase. Mol Cancer Ther 17:1240-1250
Schmainda, K M; Prah, M A; Rand, S D et al. (2018) Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project. AJNR Am J Neuroradiol 39:1008-1016
Prah, Melissa A; Al-Gizawiy, Mona M; Mueller, Wade M et al. (2018) Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics. J Neurooncol 136:13-21
Malyarenko, Dariya; Fedorov, Andriy; Bell, Laura et al. (2018) Toward uniform implementation of parametric map Digital Imaging and Communication in Medicine standard in multisite quantitative diffusion imaging studies. J Med Imaging (Bellingham) 5:011006
Newitt, David C; Malyarenko, Dariya; Chenevert, Thomas L et al. (2018) Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network. J Med Imaging (Bellingham) 5:011003
Doan, Ninh B; Nguyen, Ha S; Al-Gizawiy, Mona M et al. (2017) Acid ceramidase confers radioresistance to glioblastoma cells. Oncol Rep 38:1932-1940
Doan, Ninh B; Nguyen, Ha S; Montoure, Andrew et al. (2017) Acid ceramidase is a novel drug target for pediatric brain tumors. Oncotarget 8:24753-24761
Bell, L C; Does, M D; Stokes, A M et al. (2017) Optimization of DSC MRI Echo Times for CBV Measurements Using Error Analysis in a Pilot Study of High-Grade Gliomas. AJNR Am J Neuroradiol 38:1710-1715
Nguyen, H S; Milbach, N; Hurrell, S L et al. (2016) Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma. AJNR Am J Neuroradiol 37:2201-2208
McGarry, Sean D; Hurrell, Sarah L; Kaczmarowski, Amy L et al. (2016) Magnetic Resonance Imaging-Based Radiomic Profiles Predict Patient Prognosis in Newly Diagnosed Glioblastoma Before Therapy. Tomography 2:223-228

Showing the most recent 10 out of 54 publications